MBII - MBII STOCK NEWS

Marrone Bio Innovations (NASDAQ: MBII) announced that its shareholders approved a merger with Bioceres Crop Solutions Corp. (BIOX) during a special meeting on July 8, 2022. The merger proposal, dated March 16, 2022, has now met all necessary stockholder and regulatory approvals, with plans to finalize the transaction on July 12, 2022. Additionally, the shareholders approved compensation plans connected to the merger. The combined entity aims to enhance sustainable farming practices through innovative agricultural products, enriching crop protection and nutrition.

Marrone Bio Innovations (NASDAQ: MBII) announced its Q1 2022 financial results, reporting revenues of $11.1 million, an increase of 0.5% from Q1 2021. The gross profit fell to $6.2 million with a gross margin of 55.9%, down from 63.1% the previous year. The company faced challenges from lower specialty crop sales due to adverse weather. Operating expenses surged by 32.3% to $13.2 million, driven by merger costs with Bioceres. Despite these hurdles, MBII anticipates revenue growth in the low- to mid-teens percentage range for the first half of 2022.

Marrone Bio Innovations (NASDAQ: MBII) will release its Q1 2022 financial results on May 11, 2022, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss the results, provide corporate updates, and conduct a Q&A session. Interested participants can dial in or join via webcast. The company focuses on sustainable agricultural solutions, offering a robust product portfolio and a strong patent base. For more information, visit the Marrone Bio Innovations website.

Marrone Bio Innovations (MBII) reported a 15.5% revenue increase for the full year 2021, reaching $44.3 million, with a notable 40.2% rise in Q4 revenues. Gross profit also improved by 19.1% and 31.5% for the full year and Q4, respectively, maintaining gross margins over 59%. Although the net loss for the year was $16.6 million, it showed a 17.9% improvement from the previous year. The company anticipates continued growth in 2022 and plans to merge with Bioceres Crop Solutions.

Marrone Bio Innovations (MBII) has entered an agreement with Corteva Agriscience (CTVA), enhancing the use of MBI technologies on Corteva's row crop seeds globally. This partnership builds on existing collaborations and aims to provide sustainable crop solutions. Over 30% of MBI's annual revenue now comes from seed technologies utilized across 35 million acres of crops. The company is recognized for its innovative products, with a pipeline of 20 technologies under development, including MBI-206, which targets nematodes in soybeans and corn.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) and Marrone Bio Innovations, Inc. (NASDAQ: MBII) have announced a definitive agreement to merge in an all-stock transaction valued at approximately $236 million. Each share of MBI will convert to Bioceres shares at a ratio of 0.088. The merger aims to create a global leader in sustainable agricultural solutions, leveraging Bioceres' bionutrition expertise and MBI's biological crop protection portfolio. The deal is expected to close in Q3 2022, pending shareholder and regulatory approvals.

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) and Marrone Bio Innovations, Inc. (NASDAQ: MBII) have entered into a definitive agreement for an all-stock merger valued at approximately $236 million. Each share of MBI will be exchanged for shares of Bioceres at a fixed ratio of 0.088. This merger aims to create a global leader in sustainable agricultural solutions, combining Bioceres' expertise in bionutrition with MBI's biological crop protection products. The transaction is expected to close in Q3 2022, pending shareholder and regulatory approvals.

Marrone Bio Innovations, Inc. (NASDAQ: MBII) will release its financial results for Q4 and full year ended December 31, 2021, on March 28, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join via U.S. dial-in or international options, and a webcast will be available. Marrone Bio focuses on sustainable agricultural solutions, offering 18 products supported by over 500 patents, aimed at enhancing crop protection and health globally. For more details, visit their website.

Marrone Bio Innovations (NASDAQ: MBII) announced the resignation of CFO Sue Cheung effective March 9, 2022, due to personal reasons. LaDon Johnson, with over 30 years of experience in global corporate finance, has been appointed interim CFO while the company searches for a permanent successor. CEO Kevin Helash expressed confidence in the transition, highlighting Johnson's extensive background in agriculture and biotechnology. The company remains focused on sustainable farming practices and innovative biological products.